This protocol is a pilot study that will investigate the use of riluzole in patients with Huntington's Disease (HD). Riluzole has shown promise in the treatment of amyotrophic lateral sclerosis, another neuro- degernative disorder. The investigators will administer riluzole to 8 subjects with HD for 6 weeks as an open-label study. The study endpoint will include changes in brain lactate levels as measured by MR spectroscopy following administration of the study drug and four weeks after stopping medication.
Showing the most recent 10 out of 945 publications